- Home
- SGN vs VIVS Comparison
SGN vs VIVS Comparison
Compare SGN & VIVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGN
- VIVS
- Stock Information
- Founded
- SGN 2019
- VIVS 2007
- Country
- SGN United States
- VIVS United States
- Employees
- SGN N/A
- VIVS N/A
- Industry
- SGN
- VIVS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SGN
- VIVS Health Care
- Exchange
- SGN Nasdaq
- VIVS Nasdaq
- Market Cap
- SGN 3.8M
- VIVS 4.2M
- IPO Year
- SGN 2023
- VIVS N/A
- Fundamental
- Price
- SGN $1.08
- VIVS $1.45
- Analyst Decision
- SGN
- VIVS
- Analyst Count
- SGN 0
- VIVS 0
- Target Price
- SGN N/A
- VIVS N/A
- AVG Volume (30 Days)
- SGN 1.3M
- VIVS 64.3K
- Earning Date
- SGN 08-18-2025
- VIVS 07-07-2025
- Dividend Yield
- SGN N/A
- VIVS N/A
- EPS Growth
- SGN N/A
- VIVS N/A
- EPS
- SGN N/A
- VIVS N/A
- Revenue
- SGN $529,282.00
- VIVS $144,000.00
- Revenue This Year
- SGN N/A
- VIVS $42.38
- Revenue Next Year
- SGN N/A
- VIVS $15.42
- P/E Ratio
- SGN N/A
- VIVS N/A
- Revenue Growth
- SGN 8.42
- VIVS 32.11
- 52 Week Low
- SGN $0.44
- VIVS $1.41
- 52 Week High
- SGN $36.70
- VIVS $21.96
- Technical
- Relative Strength Index (RSI)
- SGN 52.82
- VIVS N/A
- Support Level
- SGN $0.92
- VIVS N/A
- Resistance Level
- SGN $1.35
- VIVS N/A
- Average True Range (ATR)
- SGN 0.17
- VIVS 0.00
- MACD
- SGN -0.02
- VIVS 0.00
- Stochastic Oscillator
- SGN 46.94
- VIVS 0.00
About SGN Signing Day Sports Inc.
Signing Day Sports Inc is a technology company developing and operating platforms aiming to allow significantly more student-athletes to go to college and continue playing sports. Its platform Signing Day Sports is a digital ecosystem to help athletes get discovered and recruited by coaches and recruiters across the country. It currently fully supports football and baseball, and it plans to expand the Signing Day Sports platform to include additional sports.
About VIVS VivoSim Labs Inc. Common Stock
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.